Catherine Dong

International trade regarding tobacco control, alcohol, products containing carcinogens and products associated with cancer. Internal trade regarding tobacco control, alcohol, products containing carcinogens and products associated with cancer. Funding for programs to be operated by the Canadian Cancer Society to advance cancer control. Canadian Partnership Against Cancer, as it relates to continued federal funding for the cancer control strategy Canada Health Transfer and health system bilateral funding agreements intended for provinces/territories to support the delivery of healthcare services Framework Convention on Tobacco Control, including protocols, guidelines and implementation Tobacco and Vaping Products Act, as it relates to regulations, implementation and enforcement Non-Smokers' Health Act including implementation and enforcement Food and Drugs Act and regulations, as it relates to nciotine replacement products Federal Tobacco Control Strategy, including all matters related to tobacco control Taxation, revenue measures, controlled products regulations, including implementation, for alcohol, tobacco control, products containing carcinogens and products associated with cancer. Communication regarding alcohol consumption guidance. Food and Drugs Act and regulations, as it relates to alcohol warning labels Food and Drugs Act and regulations, as it relates to restricting the advertising to children of foods high in sodium, sugars and saturated fat. Healthy Living - Supporting initiatives, legislation, regulation, policies, and programs that prevent cancer or improve the social determinants of health Adoption of HPV testing and increasing HPV vaccination rates Sustainable funding of the National Advisory Committee on Preventive Health Services to ensure timely, up?to?date cancer screening guidelines Equitable and timely access to cancer screening. Measures and funding related to the charitable sector generally Equitable access to care along the full cancer continuum for First Nations, Inuit and Métis communities Employment Insurance special benefit programs, including the sickness benefit and compassionate care benefit Canada Labour Code and Employment Insurance Act, as it relates to job-protected leave, employment insurance special benefits, return to work policies, and human rights protections for people affected by cancer Access to information and support to make decisions regarding end-of-life care, including Medical Assistance In Dying Supports for mental health during people's cancer journeys Implementation and funding of the National Grief Action Plan as part of the government's work on palliative care and mental health Canada Health Act as it relates to access to care, including long-term, home, and palliative care National Caregiving Strategy Financial supports for caregivers, including the Canada Caregiver Credit Implementation of the Framework on Palliative Care in Canada and integration of a palliative approach to care in our health system, including national standards and data, care provider training, research, and implementation of the National Grief Action Plan and distinctions?based frameworks for First Nations, Inuit and Métis people Setting and measuring pan-Canadian wait time benchmarks and targets and measures to address them, including addressing healthcare shortages, increased and sustainable funding for care, infrastructure and equipment, targeted strategic funding to PTs for workforce shortages, particularly in rural and remote communities. Sustained core funding for federal research agencies, improved coverage of indirect research costs, Canadian research sovereignty, strengthening capacity and the economic benefits of domestic research, research commercialization. Increasing access to care including models of care, removing barriers to care, particularly for underserved communities, using innovative approaches to improve access to care including AI to improve timely diagnosis and treatment. Issu

Postal service disruption and the significant hardships these disruptions cause for Canadians and on health charities We ask the federal government to fund MS research in partnership with MS Canada, leveraging our connections and expertise to focus and further our understanding of MS, pursue leading-edge research on repair and regeneration, and explore prevention strategies, including targeting the Epstein-Barr virus (EBV). Safe Long-Term Care Act with respect to persons affected by MS National Housing Strategy with respect for persons with MS and other chronic conditions and disabilities Measures and funding for the charitable sector generally Home care, with respect to creation with provincial/ territorial governments programs relating to increased home care for persons with MS and other disabilities/ diseases and the support of caregivers Federal Budget: Allocate funding for the Canada Disability Benefit, the Employment Insurance Sickness Benefit; health research; access to treatment and care; and other budgetary policy as it relates to MS. Establishment of national strategy for neurological conditions, with respect to persons with MS and other neurological conditions. Employment Insurance sickness benefits, with respect to creation of flexible benefits for persons with MS and other episodic disabilities Disability Tax Credit with respect to making it refundable and ensuring eligibility for Canadians with episodic disabilities Comprehensive disability income programs, with respect to persons with MS and other chronic and episodic disabilities CIHR as it relates to federal funding & long term investment in health research Canada Pension Plan – Disability with respect to eligibility for persons with MS and other chronic and episodic disabilities Canada Health Transfer - health system funding transfer and agreements intended for provinces/territories to support the delivery of healthcare services, including MS care Canada Health Act and regulations, as it relates to long-term and home care Bill C-64, An Act Respecting Pharmacare with respect for persons with MS and other chronic conditions and disabilities Access to treatments as it relates to the current regulatory and price negotiation processes to enhance timely access to all Health Canada approved MS disease-modifying therapies, with respect to the National Strategy for Drugs for Rare Diseases and national pharmacare.

Policies aimed at reinforcing pharmaceutical supply chain. Discussion regarding the launch of new branded product in the rare disease space Improvements to the supports offered by the federal government to support R&D; in particular, generic drug research and development. Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project. Policies aimed at facilitating generic drug repurposing. Discussion on the opioid crisis and the Health minister's expectations from pharmaceutical manufacturers Discussion of regulatory impediments to the launch of pediatric formulations of branded and generic products. Discussion of a possible Therapeutics Products Directorate ("TPD") workstream on complex generics regulatory pathways.